ADQUEY is a non-steroidal topical phosphodiesterase-4 (PDE4) inhibitor. The product will compete in a US market estimated at around $1.3 billion for the 12 months ended July 2026, according to IQVIA MAT.
The launch marks Acrotech’s entry into the US dermatology market. To support ADQUEY and its long-term dermatology plans, the company has established a dedicated dermatology business unit with commercial capabilities across marketing, sales and field-based engagement.
ALSO READ | Aurobindo Pharma Q1 Results: Profit, EBITDA beat estimates on strong global demand
The dermatology business will focus on building awareness of ADQUEY, engaging with dermatology healthcare professionals and supporting patients through their treatment journey. It will also develop the infrastructure and expertise required to expand Acrotech’s presence in specialty dermatology.
Difamilast was originally discovered by Otsuka Pharmaceutical and licensed to Acrotech Biopharma for commercialisation in the US. The launch is part of Acrotech’s strategy to expand its portfolio of innovative medicines and establish focused commercial platforms in areas of significant patient need.
Ashish Anvekar, President of Acrotech Biopharma, said, “The launch of ADQUEY is an important milestone for Acrotech and marks our entry into the US dermatology market with a differentiated treatment option for patients living with atopic dermatitis.
ALSO READ | Aurobindo Pharma to launch ₹800 crore buyback at ₹1,475 per share from April 23
We are building more than a commercial organisation around a single product. We are establishing a dedicated dermatology platform designed to support ADQUEY today while creating the capabilities to pursue additional opportunities that can address important unmet needs in dermatologic care.”
Shares of Aurobindo Pharma Ltd ended at ₹1,666.50, down by ₹36.50, or 2.14%, on the BSE.